Журнал кардиореспираторных исследований 2025. №3
Maqola mavzusi
CLINICAL AND GENETIC PREDICTION OF CHRONIC KIDNEY DISEASE RISK IN PATIENTS WITH METABOLIC SYNDROME (16-19)
Mualliflar
Mirzaev Rizamat Ziyadullaevich, Nosirova Dilangiz Akbarovna
Muassasa
Samarkand State Medical University
Annotatsiya
Due to the increasing prevalence of metabolic syndrome (MS) worldwide, predicting the risk of chronic kidney disease (CKD), one of the frequent complications of MS, has become particularly relevant. The purpose of this review article is to highlight current data on the relationship between MS and CKD, multicenter studies conducted, and genetic factors, as well as prospects for clinical and genetic prediction. Metabolic syndrome comprises a combination of abdominal obesity, arterial hypertension, carbohydrate metabolism disorders, and dyslipidemia. This syndrome independently affects the risk of kidney damage. According to an Iranian cohort study (15,255 participants), kidney damage associated with MS was detected with a hazard ratio (HR) of 1.51. A meta-analysis of 32 cohorts (over 400,000 observations) established that MS increases the risk of chronic renal failure by 47% (relative risk, RR = 1.47). A genetically determined decrease in estimated glomerular filtration rate (eGFR) has been confirmed in Mendelian randomization studies. An association between ALPK1, CDH4, and PTPRN2 genotypes and increased risk of CKD was observed in Japanese cohorts. These genes influence fat metabolism, insulin resistance, and chronic inflammation. Modern approaches include comprehensive assessment: clinical parameters (eGFR, albuminuria, C-reactive protein, HOMA-IR), genotyping, and artificial intelligence for constructing risk models. This opens up opportunities for early diagnosis and targeted therapy (RAAS blockade, SGLT2 inhibitors, metabolic correction).
Kalit so'zlar
metabolic syndrome, chronic kidney disease, genetic markers, risk prediction, gene polymorphisms, Mendelian randomization, insulin resistance, albuminuria, eGFR, clinical-genetic models
Adabiyotlar
1. Eckardt K.U., Coresh J., Devuyst O. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013. 2. Ritz E., Koleganova N., Piecha G. Is there an obesity paradox in chronic kidney disease? Nephrol Dial Transplant. 2011. 3. Yang Q., Guo C.Y., Cupples L.A., Levy D., Fox C.S. Genetic variants associated with metabolic syndrome predict kidney disease. Nephrol Dial Transplant. 2010. 4. Gorski M., Tin A., Garnaas M. et al. Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int. 2017. 5. Kato N., Loh M., Takeuchi F. et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015. 6. Lin L, Pan X, Feng Y, et al. Chronic kidney disease combined with metabolic syndrome is a non‑negligible risk factor. Ther Adv Endocrinol Metab. 2024;15:20420188241252309 7. Li X, Liang Q, Zhong J, Gan L, Zuo L. The Effect of Metabolic Syndrome and Its Individual Components on Renal Function: A Meta‑Analysis. J Clin Med. 2023;12(4):1614 8. Du Q, Jiang Y, Liu Y. Prevalence of metabolic syndrome in patients with end‑stage renal disease: a systematic review and meta‑analysis. Int Urol Nephrol. 2024;56:1057–1069 9. link.springer.com 10. BMC Nephrology. Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? Meta‑analysis. 2024;25:467 11. Guo Z, et al. Causal association of metabolic syndrome with chronic kidney disease progression: A Mendelian randomization study. Pediatr Diabetes. 2024 12. Hou Y, Xiao Z, Zhu Y, et al. Blood metabolites and chronic kidney disease: a Mendelian randomization study. BMC Med Genomics. 2024;17:147 13. Chen Y, Torta F, Koh HWL, et al. Metabolomics profiling… renal function decline. Diabetologia. 2024 14. Mira FS, Oliveiros B, Carreira IM, et al. Genetic Variants Related to Increased CKD Progression—A Systematic Review. Biology. 2025;14(1):68 15. Scurt FG, et al. Association of metabolic syndrome and chronic kidney disease. Obesity Rev. 2024 16. Panwar B, Hanks LJ, Tanner RM, et al. Obesity, metabolic health, and the risk of end‑stage renal disease. Kidney Int. 2015 17. Lea J, Cheek D, Thornley‑Brown D, et al. Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans. Am J Kidney Dis. 2008 18. Drawz P, Rahman M. Chronic Kidney Disease. Ann Intern Med. 2015;162:ITC1–ITC16 19. Wang M, Xia M, Yang H, et al. Interaction effect of blood glucose and pressure on the risk of chronic kidney disease. Endocrine. 2022 20. Zhang Q, Zhang K, Zhu Y, et al. Exploring genes for immunoglobulin A nephropathy… mendelian randomization. BMC Med Genomics. 2023 21. Ponte B, Sadler MC, Olinger E, et al. Mendelian randomization… uromodulin, blood pressure and CKD. Kidney Int. 2021 22. Fan C, Gao Y, Sun Y. Integrated multiple-microarray analysis… diabetic nephropathy. Front Endocrinol. 2023 23. Morris AP, Le TH, Wu H, et al. Trans-ethnic kidney function association study… causal genes. Nat Commun. 2019 24. Kanai M, Akiyama M, Takahashi A, et al. Genetic analysis of quantitative traits… Japanese population. Nat Genet. 2018 25. Zhang D, et al. A Mendelian randomization study of glycemia, adiposity, and CKD. Genome Med. 2020 26. Dana Z, Naseer AA, Toro B, Swaminathan S. Integrated Machine Learning and Survival Analysis… CKD Risk Stratification. 2024